^
Association details:
| Biomarker: | Chr del(13)(q12.12) |
|---|---|
| Cancer: | Gastric Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
1425P - Immune microenvironment and genomic alterations interpret heterogeneous response to immunotherapy in EBV-associated gastric carcinoma
Published date:
09/13/2021
Excerpt:
Furthermore, patients with 13q12.12 deletion had unfavorable PFS and OS (P =0.070; P =0.332)….SMARCA4 and 13q12.12 deletion were potential biomarkers of EBVaGC patients regarding to ICB.